PLX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
21.9M
+10.2%
19.9M
-41.0%
33.8M
+270.0%
9.1M
-48.9%
17.9M
Cost of Revenue
7.9M
+1.5%
7.8M
+88.1%
4.1M
-10.7%
4.6M
-44.5%
8.3M
Gross Profit
14.0M
+15.8%
12.1M
-59.0%
29.6M
+557.9%
4.5M
-52.7%
9.5M
Operating Expenses
10.0M
+34.0%
7.5M
-12.0%
8.5M
-7.5%
9.2M
+23.9%
7.4M
R&D
6.9M
+59.1%
4.4M
-19.8%
5.4M
-3.7%
5.6M
+26.1%
4.5M
SG&A
3.1M
-1.0%
3.1M
+2.0%
3.1M
-13.5%
3.5M
+20.4%
2.9M
Operating Income
4.0M
-13.4%
4.7M
-77.9%
21.1M
+554.0%
-4658000
-318.6%
2.1M
EBITDA
4.5M
-12.0%
5.1M
-76.4%
21.6M
+604.6%
-4271000
-270.6%
2.5M
Net Income
4.0M
+4.9%
3.8M
-79.4%
18.3M
+432.8%
-5504000
-333.7%
2.4M
EPS (Basic)
$0.05
+0.0%
$0.05
-78.3%
$0.23
+428.6%
$-0.07
-333.3%
$0.03
EPS (Diluted)
$0.05
+0.0%
$0.05
-77.3%
$0.22
+414.3%
$-0.07
-333.3%
$0.03
Shares (Diluted)
83.6M
+1.2%
82.6M
-0.6%
83.0M
+10.0%
75.5M
-6.6%
80.8M
Protalix BioTherapeutics (PLX) — Financials